Late Thursday, Eli Lilly & Co. (NYSE:LLY) posted financial results for the third quarter. Eli Lilly reported a net loss of $465.6 million, or 43 cents per share, in part due to a $1.48 billion charge to settle investigations related to its drug Zyprexa. Without the charge, the company surpassed analysts' earnings estimates by 2 cents. Last year the company saw net income of $926.3 million, or 85 cents per share. On Oct. 6, Eli Lilly agreed to a $6.5 billion transaction to acquire ImClone. The company expects to earn between $2.44 and $2.49 per share for fiscal 2008. Shares of Eli Lilly gained $1.37 to close at $33.48.

Contact Chip Brian

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at www.TradeTheTrend.com/signup.html